Local and regional treatment response by 18FDG-PET-CT-scans 4  weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC

Improved local control attributes to improved overall survival (OS) in locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (CCRT) [1]. Many adjustments of chemo- and radiotherapy (RT) regimens have been explored to increase outcome [1]. One such adjustment is the combination of daily low dose cisplatin with hypofractionated radiotherapy, which has been explored in several EORTC-trials and in a Dutch randomized phase II Raditux-trial (NTR2230) investigating the addition of Cetuximab to CCRT [2 –4].

Source: Radiotherapy and Oncology - November 21, 2019 Category: Radiology Authors: Judi N.A. van Diessen, Matthew La Fontaine, Michel M. van den Heuvel, Erik van Werkhoven, Iris Walraven, Wouter V. Vogel, Jos é S.A. Belderbos, Jan-Jakob Sonke Tags: Original Article Source Type: research